JP2005535670A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535670A5
JP2005535670A5 JP2004520655A JP2004520655A JP2005535670A5 JP 2005535670 A5 JP2005535670 A5 JP 2005535670A5 JP 2004520655 A JP2004520655 A JP 2004520655A JP 2004520655 A JP2004520655 A JP 2004520655A JP 2005535670 A5 JP2005535670 A5 JP 2005535670A5
Authority
JP
Japan
Prior art keywords
function
pharmacologically active
platelet aggregation
modified amino
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004520655A
Other languages
English (en)
Japanese (ja)
Other versions
JP4541884B2 (ja
JP2005535670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/007739 external-priority patent/WO2004006907A1/en
Publication of JP2005535670A publication Critical patent/JP2005535670A/ja
Publication of JP2005535670A5 publication Critical patent/JP2005535670A5/ja
Application granted granted Critical
Publication of JP4541884B2 publication Critical patent/JP4541884B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004520655A 2002-07-17 2003-07-16 血小板凝集の阻害のための修飾アミノ酸 Expired - Fee Related JP4541884B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39689802P 2002-07-17 2002-07-17
PCT/EP2003/007739 WO2004006907A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Publications (3)

Publication Number Publication Date
JP2005535670A JP2005535670A (ja) 2005-11-24
JP2005535670A5 true JP2005535670A5 (cg-RX-API-DMAC10.html) 2006-08-24
JP4541884B2 JP4541884B2 (ja) 2010-09-08

Family

ID=30116066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004520655A Expired - Fee Related JP4541884B2 (ja) 2002-07-17 2003-07-16 血小板凝集の阻害のための修飾アミノ酸

Country Status (12)

Country Link
US (3) US20060106110A1 (cg-RX-API-DMAC10.html)
EP (1) EP1556027B1 (cg-RX-API-DMAC10.html)
JP (1) JP4541884B2 (cg-RX-API-DMAC10.html)
CN (1) CN1668290B (cg-RX-API-DMAC10.html)
AT (1) ATE538782T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003257473A1 (cg-RX-API-DMAC10.html)
BR (1) BR0312712A (cg-RX-API-DMAC10.html)
CA (1) CA2492378C (cg-RX-API-DMAC10.html)
ES (1) ES2379949T3 (cg-RX-API-DMAC10.html)
PT (1) PT1556027E (cg-RX-API-DMAC10.html)
TW (1) TW200403052A (cg-RX-API-DMAC10.html)
WO (1) WO2004006907A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
DE60325906D1 (de) 2003-08-08 2009-03-05 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
EP2463386B1 (en) 2005-06-15 2017-04-12 Complete Genomics Inc. Nucleic acid analysis by random mixtures of non-overlapping fragments
SG165397A1 (en) * 2005-09-19 2010-10-28 Emisphere Tech Inc Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid
BRPI0716261A2 (pt) * 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
US8895777B2 (en) 2006-08-31 2014-11-25 Emisphere Technologies Inc Compounds and compositions for delivering active agents
MX2010004716A (es) 2007-11-02 2010-12-17 Emisphere Tech Inc Metodo para tratar la deficiencia de vitamina b12.
MX2012009914A (es) * 2010-02-24 2013-03-05 Emisphere Tech Inc Terapia oral de b12.
RU2504536C1 (ru) * 2012-08-20 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Производное амида салициловой кислоты, обладающее антибактериальной, противогрибковой и антилизоцимной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1998034632A1 (en) * 1997-02-07 1998-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Similar Documents

Publication Publication Date Title
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
JP2004210767A5 (cg-RX-API-DMAC10.html)
JP2005526147A5 (cg-RX-API-DMAC10.html)
JP2002532112A5 (cg-RX-API-DMAC10.html)
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
NL300650I2 (nl) Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en Olodaterolhydrochloride
JP2004529078A5 (cg-RX-API-DMAC10.html)
JP2004523498A5 (cg-RX-API-DMAC10.html)
AU2002328343A1 (en) Wax-based compositions and the use thereof as body care agents
EP1513403A4 (en) USE OF CARDIOTONIC GLUCOSIDES FOR THE TREATMENT OF MUCOVICIDOSIS AND OTHER IL-8 DEPENDENT DISORDERS
ZA200305173B (en) Omega-Aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells.
DE60117046D1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
JP2005535670A5 (cg-RX-API-DMAC10.html)
JP2008519846A5 (cg-RX-API-DMAC10.html)
JP2003526626A5 (cg-RX-API-DMAC10.html)
WO2003005880A3 (en) Replikin peptides and uses thereof
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
IL166257A (en) 2-Amino Compounds Benzothiazole Sulfonamides, and Their Use in the Preparation of HIV Protease Inhibition Drugs
JP2006199609A5 (cg-RX-API-DMAC10.html)
JP2009019158A5 (cg-RX-API-DMAC10.html)
JP2006527741A5 (cg-RX-API-DMAC10.html)
RU99126233A (ru) Антиаритмическое средство
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
JPH10273446A5 (cg-RX-API-DMAC10.html)